The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Open accessAbstract
Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design criterion for new combinations. We review evidence that independent drug action, described in 1961, explains the efficacy of many practice-changing combination therapies: it provides populations of patients with heterogeneous drug sensitivities multiple chances of benefit from at least one drug. Understanding response heterogeneity could reveal predictive or pharmacodynamic biomarkers for more precise use of existing drugs and realize the benefits of additivity or synergy. Significance: The model of independent drug action represents an effective means to predict the magnitude of benefit likely to be observed in new clinical trials for combination therapies. The “bet-hedging” strategy implicit in independent action suggests that individual patients often benefit from only a subset—sometimes one—of the drugs in a combination. Personalized, targeted combination therapy, consisting of agents likely to be active in a particular patient, will increase, perhaps substantially, the magnitude of therapeutic benefit. Precision approaches of this type will require a better understanding of variability in drug response and new biomarkers, which will entail preclinical research on diverse panels of cancer models rather than studying drug synergy in unusually sensitive models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“For example, fewer than half of biomarker-positive patients respond initially to trastuzumab (Herceptin) in HER2-overexpressing breast cancers or to MEK/BRAF inhibitors in BRAF V600E/K -mutant melanomas (39, 40).”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
Giesen, C., Wang, H. A. O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P. J., Grolimund, D., Buhmann, J. M., Brandt, S., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2869 · Cited by 1,951
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
(2016) · Wiley eBooks · doi:10.1002/9781119000822 · Cited by 1,148
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115 · cited 1×
“…and synergy into reliable experimental methodologies to detect these mechanisms is not straightforward even in cell lines, and a series of papers dating back to at least 1977 (65) has raised concerns about the wide-spread misuse of experiments and definitions associated with this terminology.”
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Lin, J.-R., Izar, B., Wang, S., Yapp, C., Mei, S., Shah, P. M., Santagata, S., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.31657 · Cited by 692
Self-citationTherapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Self-citationImmunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 667
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Self-citationLim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 630
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
Stewart, L. A., & Tierney, J. F. (2002) · Evaluation & the Health Professions · doi:10.1177/0163278702025001006 · Cited by 571
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Predicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544
Statistics review 12: survival analysis.
Bewick, V., Cheek, L., & Ball, J. (2004) · Critical Care · doi:10.1186/cc2955 · Cited by 516
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Han, K., Jeng, E. E., Hess, G. T., Morgens, D. W., Li, A., & Bassik, M. C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3834 · Cited by 498
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0062 · Cited by 463
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., Pogrebniak, K., Sandoval, J., Cassidy, J. W., Tufegdzic-Vidakovic, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 448
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Longo, D. L., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1516564 · Cited by 419
Richman, D. D. (2001) · Nature · doi:10.1038/35073673 · Cited by 419
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Menden, M. P., Wang, D., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T., Kang, J., Jeon, M., Wolfinger, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 363
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359
Nichols, C. R., Catalano, P. J., Crawford, E. D., Vogelzang, N. J., Einhorn, L. H., & Loehrer, P. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1287 · Cited by 348
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
FREI, E., KARON, M., LEVIN, R. H., FREIREICH, E. J., TAYLOR, R. J., HANANIAN, J., SELAWRY, O., HOLLAND, J. F., HOOGSTRATEN, B., WOLMAN, I. J., et al. (1965) · Blood · doi:10.1182/blood.v26.5.642.642 · Cited by 325
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller, W. H., Carlino, M. S., Fisher, R., Long, G. V., Hodi, F. S., Tsoi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0476-5 · Cited by 323
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
Metrics other than potency reveal systematic variation in responses to cancer drugs
Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W., & Sorger, P. K. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1337 · Cited by 314
Self-citationModeling precision treatment of breast cancer
Daemen, A., Griffith, O. L., Heiser, L. M., Wang, N. J., Enache, O. M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J. E., Griffith, M., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r110 · Cited by 295
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0317 · Cited by 291
Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L. J., Kyriakides, S., Costa, A., Cufer, T., Albain, K. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp235 · Cited by 241
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
Self-citationCandidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233
Methods for High-throughput Drug Combination Screening and Synergy Scoring
He, L., Kulesskiy, E., Saarela, J., Turunen, L., Wennerberg, K., Aittokallio, T., & Tang, J. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7493-1_17 · Cited by 232
Die quantitativen Probleme der Pharmakologie
Loewe, S. (1928) · Ergebnisse der Physiologie · doi:10.1007/bf02322290 · Cited by 229
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 223
Frei, E., Freireich, E. J., Gehan, E., Pinkel, D., Holland, J. F., Selawry, O., Haurani, F., Spurr, C. L., Hayes, D. M., James, G. W., et al. (1961) · Blood · doi:10.1182/blood.v18.4.431.431 · Cited by 222
What is synergy? The Saariselkä agreement revisited
Tang, J., Wennerberg, K., & Aittokallio, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00181 · Cited by 217
Del Gaizo Moore, V., & Letai, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2011.12.021 · Cited by 204
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
Kerantzas, C. A., & Jacobs, W. R. (2017) · mBio · doi:10.1128/mbio.01586-16 · Cited by 202
High-Throughput Methods for Combinatorial Drug Discovery
Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 197
The Use of Drugs in Combination for the Treatment of Cancer: Rationale and Results
DeVita, V. T., & Schein, P. S. (1973) · New England Journal of Medicine · doi:10.1056/nejm197305102881905 · Cited by 190
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182
A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia
FREI, E., HOLLAND, J. F., SCHNEIDERMAN, M. A., PINKEL, D., SELKIRK, G., FREIREICH, E. J., SILVER, R. T., GOLD, G. L., & REGELSON, W. (1958) · Blood · doi:10.1182/blood.v13.12.1126.1126 · Cited by 179
Advances in understanding tumour evolution through single-cell sequencing
Kuipers, J., Jahn, K., & Beerenwinkel, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.001 · Cited by 170
Defining principles of combination drug mechanisms of action
Pritchard, J. R., Bruno, P. M., Gilbert, L. A., Capron, K. L., Lauffenburger, D. A., & Hemann, M. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210419110 · Cited by 168
Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data
Sidorov, P., Naulaerts, S., Ariey-Bonnet, J., Pasquier, E., & Ballester, P. J. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00509 · Cited by 168
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1295 · Cited by 159 · cited 1×
“predicting some drug responses, for example, NTRK fusions and sensitivity”
Coussy, F., Botty, R. E., Château‐Joubert, S., Dahmani, A., Montaudon, É., Leboucher, S., Morisset, L., Painsec, P., Sourd, L., Huguet, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2625 · Cited by 159
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Julkunen, H., Cichońska, A., Gautam, P., Szedmák, S., Douat, J., Pahikkala, T., Aittokallio, T. A., & Rousu, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19950-z · Cited by 147
Palmer, A. C., Chidley, C., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.50036 · Cited by 145
Self-citationRecent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 125
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 116
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J. L., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 116
Self-citationAddressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy
Zhao, B., Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0465 · Cited by 105
Sicklick, J. K., Kato, S., Okamura, R., Patel, H., Nikanjam, M., Fanta, P. T., Hahn, M. E., De, P. K., Williams, C. B., Guido, J., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00969-w · Cited by 99
Danchev, V., Min, Y., Borghi, J., Baiocchi, M., & Ioannidis, J. P. A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33972 · Cited by 94
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Narayan, R. S., Molenaar, P., Teng, J., Cornelissen, F. M. G., Roelofs, I., de Menezes, R. X., Dik, R., Lagerweij, T., Broersma, Y., Petersen, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16735-2 · Cited by 94
Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 87
Self-citationRationalizing combination therapies
(2017) · Nature Medicine · doi:10.1038/nm.4426 · Cited by 84
Ling, A. L., & Huang, R. S. (2020) · Nature Communications · doi:10.1038/s41467-020-19563-6 · Cited by 81
Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice.
Law, L. W. (1952) · PubMed · Cited by 72
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Ianevski, A., Kononov, A., Timonen, S., Aittokallio, T. A., & Giri, A. K. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007604 · Cited by 72
Schmidt, E. V., Chisamore, M. J., Chaney, M. F., Maradeo, M. E., Anderson, J. R., Baltus, G. A., Pinheiro, E. M., & Uebele, V. N. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20833 · Cited by 66
How valid are claims for synergy in published clinical studies?
Ocaña, A., Amir, E., Yeung, C., Šeruga, B., & Tannock, I. F. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr608 · Cited by 65
Mechanisms of drug interactions between translation-inhibiting antibiotics
Kavčič, B., Tkačik, G., & Bollenbach, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17734-z · Cited by 65
Pharmacodynamic Biomarkers: Falling Short of the Mark?
Gainor, J. F., Longo, D. L., & Chabner, B. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3132 · Cited by 55
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 53
Modeling Tumor Clonal Evolution for Drug Combinations Design
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.001 · Cited by 47
Mitri, Z. I., Parmar, S. S., Johnson, B., Kolodzie, A., Keck, J. M., Morris, M., Guimarães, A. R., Beckett, B. R., Borate, U., Lopez, C. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1733-y · Cited by 47
5. An Experimental Research on the Antagonism between the Actions of Physostigma and Atropia
Fraser, T. R. (1872) · Proceedings of the Royal Society of Edinburgh · doi:10.1017/s0370164600042565 · Cited by 42
Diaz, J. E. L., Ahsen, M. E., Schaffter, T., Chen, X., Realubit, R. B., Karan, C., Califano, A., Losic, B., & Stolovitzky, G. A. (2020) · eLife · doi:10.7554/elife.52707 · Cited by 40
Nowakowski, G. S., Feldman, T. A., Rimsza, L. M., Westin, J. R., Witzig, T. E., & Zinzani, P. L. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0208-6 · Cited by 39
A pharmacodynamic model of clinical synergy in multiple myeloma
Sudalagunta, P. R., Silva, M. C., Canevarolo, R. R., Alugubelli, R. R., DeAvila, G., Tungesvik, A., Perez, L. E., Gatenby, R. A., Gillies, R. J., Baz, R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102716 · Cited by 39
Stockslager, M. A., Malinowski, S. W., Touat, M., Yoon, J. C., Geduldig, J. E., Mirza, M., Kim, A. S., Wen, P. Y., Chow, K.-H., Ligon, K. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109788 · Cited by 39
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Lazzari, C., Bulotta, A., Ducceschi, M., Viganò, M. G., Brioschi, E., Corti, F., Gianni, L., & Gregorc, V. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00004 · Cited by 37
Update on emerging biomarkers in lung cancer
Bernicker, E., Allen, T. C., & Cagle, P. T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.46 · Cited by 36
Principles of Dose, Schedule, and Combination Therapy
Hait, W. N., & Eder, J. P. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm055.pub2 · Cited by 32
Drugs that lack single-agent activity: are they worth pursuing in combination?
Gyawali, B., & Prasad, V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.27 · Cited by 28
A critical evaluation of methods to interpret drug combinations
Twarog, N. R., Connelly, M., & Shelat, A. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61923-1 · Cited by 27
Berge, E. M., Lu, X. J. D., Maxson, D. A., Barón, A. E., Gadgeel, S. M., Solomon, B., Doebele, R. C., Varella-Garcia, M., & Camidge, D. R. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.06.005 · Cited by 24
Current and Evolving Methods to Visualize Biological Data in Cancer Research
Chia, P. L., Gedye, C. A., Boutros, P. C., Wheatley‐Price, P., & John, T. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw031 · Cited by 23
Chang, C.-H., Liu, W., Hung, H.-C., Gean, C.-Y., Tsai, H., Su, C.-L., & Gean, P. (2017) · BMC Cancer · doi:10.1186/s12885-017-3924-y · Cited by 21
Outlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery
Ochs, M. F., Farrar, J. E., Considine, M., Wei, Y., Meshinchi, S., & Arceci, R. J. (2014) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2013.153 · Cited by 17
Palmer, A. C., Plana, D., Gao, H., Korn, J. M., Yang, G., Green, J., Zhang, X., Velazquez, R., McLaughlin, M. E., Ruddy, D. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3850 · Cited by 17
Self-citationIndependent drug action and its statistical implications for development of combination therapies
Chen, C., Liu, F., Ren, Y., Suttner, L. H., Sun, Z., Shentu, Y., & Schmidt, E. V. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106126 · Cited by 17
Sharma, A., & Rani, R. (2018) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720018500178 · Cited by 15
Sun, L., Wu, C., Li, X., Chen, C., & Schmidt, E. V. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106434 · Cited by 12
Cited by
Ianevski, A., Giri, A. K., & Aittokallio, T. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac382 · Cited by 778
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Plana, D., Palmer, A. C., & Sorger, P. K.
- Venue
- Cancer Discovery
- Published
- 2022-03-01
- Volume
- 12
- Issue
- 3
- Pages
- 606-624
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4205686435
- Cited by
- 307
- References
- 124
- FWCI
- 22.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.